258 related articles for article (PubMed ID: 22904679)
21. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.
Pagliarulo V; Ancona P; Niso M; Colabufo NA; Contino M; Cormio L; Azzariti A; Pagliarulo A
Mol Cancer; 2013 May; 12():47. PubMed ID: 23705854
[TBL] [Abstract][Full Text] [Related]
22. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
24. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Xia W; Zhao T; Lv J; Xu S; Shi J; Wang S; Han X; Sun Y
J Cell Biochem; 2009 Sep; 108(1):181-94. PubMed ID: 19562670
[TBL] [Abstract][Full Text] [Related]
25. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Lev-Ari S; Zinger H; Kazanov D; Yona D; Ben-Yosef R; Starr A; Figer A; Arber N
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S276-80. PubMed ID: 16507392
[TBL] [Abstract][Full Text] [Related]
26. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
27. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
28. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
Cervello M; Bachvarov D; Cusimano A; Sardina F; Azzolina A; Lampiasi N; Giannitrapani L; McCubrey JA; Montalto G
OMICS; 2011 Jun; 15(6):383-92. PubMed ID: 21410330
[TBL] [Abstract][Full Text] [Related]
29. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Yusup G; Akutsu Y; Mutallip M; Qin W; Hu X; Komatsu-Akimoto A; Hoshino I; Hanari N; Mori M; Akanuma N; Isozaki Y; Matsubara H
Int J Oncol; 2014 Apr; 44(4):1146-52. PubMed ID: 24535229
[TBL] [Abstract][Full Text] [Related]
30. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.
Gallouet AS; Travert M; Bresson-Bepoldin L; Guilloton F; Pangault C; Caulet-Maugendre S; Lamy T; Tarte K; Guillaudeux T
Clin Cancer Res; 2014 May; 20(10):2663-73. PubMed ID: 24637636
[TBL] [Abstract][Full Text] [Related]
31. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
32. [Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].
Liu JP; Wei HB; Zheng ZH; Guo WP; Fang JF
Yao Xue Xue Bao; 2009 Dec; 44(12):1353-8. PubMed ID: 21351468
[TBL] [Abstract][Full Text] [Related]
33. Different cell cycle modulation by celecoxib at different concentrations.
Kim YM; Pyo H
Cancer Biother Radiopharm; 2013 Mar; 28(2):138-45. PubMed ID: 23268707
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
35. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
36. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
37. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
Zatelli MC; Luchin A; Tagliati F; Leoni S; Piccin D; Bondanelli M; Rossi R; degli Uberti EC
Endocr Relat Cancer; 2007 Dec; 14(4):1029-38. PubMed ID: 18045954
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.
Li W; Jiang HR; Xu XL; Wang J; Zhang J; Liu ML; Zhai LY
Int J Mol Sci; 2010 Oct; 11(10):3999-4013. PubMed ID: 21152316
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
